the patient stress provoked by intensive examinations with the risk of false-positives.
Armed with such evidence, the rationale for using such a strict follow-up schedule based on chest X-ray vanishes and should not be considered the 'basic standard' in the ESMO MCR. Recently, the European Germ Cell Cancer Consensus Group (EGCCCG) has developed guidelines on diagnosis and treatment of GCT based on the highest evidence level available: no specific recommendations have been given for follow-up [9] . The optimum follow-up strategy of GCT patients remains controversial. It is essential to take into account all the evidence to make correct decisions in the follow-up management. No firm guidelines can be given. The intensity of the follow-up investigations should be modified according to the risk of recurrence/progression among GCT patients, stage and sites of disease, and natural history of histological subtypes.
In addition, in previous years other issues have emerged during the follow-up of these patients as secondary tumours, long-term cardiovascular and renal side-effects, hearing impairment, metabolic syndrome and gonadal dysfunction, which can be in a large part influenced by the treatment [10] [11] [12] . In the future, monitoring and moderating these specific long-term complications will be part of the follow-up management. This will require new large studies to target this approach. In this fashion, the role of referring institutions and cooperative groups will be important. 
